 | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
The Singapore Cord Blood Bank (Abbreviation: SCBB) is Singapore's only public cord blood bank that collects, processes and stores donated umbilical cord blood for use in stem cell transplants. Its cord blood units may be searched for use by qualifying transplant centers around the world.
As a public cord blood bank, SCBB does not charge cord blood donors for its services. However, as the cord blood is donated altruistically, the donor relinquishes any claims to it after donation. This contrasts with a private cord blood bank where parents pay a fee for the cord blood banking services, but retain ownership over the use of their cord blood.
Cord blood is the blood that circulates through the umbilical cord from the foetus to the placenta. After delivery, the placenta is almost always thrown away. Yet this humble umbilical cord has become a life saving and precious commodity, because cord blood is rich in blood stem cells.
Blood stem cells are young or immature cells that can transform into other forms of essential blood cell types (pluripotent), such as red blood cells, white blood cells and platelets. The use of blood stem cells has emerged as a potentially curative option for the treatment of several diseases, including blood cancers (such as leukemia and lymphoma), and severe anaemia (such as myelodysplastic syndrome, thalassemia major and severe aplastic anaemia). [1] What type of disease can be treated by cord blood stem cell? A new horizon has opened up in modern medical science. Although stem cells are collected from this cord blood and used to achieve significant success in the treatment of many deadly diseases, its use is increasing in developing countries. For example in the United States more than 10,000 people are treated each year for serious illnesses.
1. Leukemia’s: such as Acute Myelogenous Leukemia 2. Lymphomas: non hodking's Lymphoma, Lymph proliferative disease 3. Bone marrow disease: like Paroxysmal Nocturnal Hemoglobinuria 4. Sickle Cell Anemia’s, 5. Thalassemia 6.Immune Deficiencies disease 7. Metabolic problem 8.Blood cell disorders 9.Histocytosis problem… etc.Besides, scientists are making every effort and testing whether this cord blood can be used to treat other diseases. For example - Diabetes, Brain injuries etc disease.
Officially opened on 28 September 2005 by Health Minister Mr. Khaw Boon Wan, Singapore Cord Blood Bank was established in response to demands from Haematologists and Paediatricians in Singapore. [2]
Singaporean patients who needed stem cell transplants were then facing difficulties in obtaining Human Leukocyte Antigen (HLA) matched stem cell units because of the relative scarcity of stem cell donors that matched Singapore's main ethnic profiles i.e. Chinese, Malay and Indian ethnicities. SCBB was conceived as a solution to this problem. Donation of cord blood by Singaporeans would significantly increase the probability of obtaining matched cord blood units for the treatment of Singaporean patients.
Having joined the WMDA and NMDP network in 2006 and 2007 respectively, SCBB allows patients of Asian descent all over the world to search SCBB's inventory for a matching cord blood unit as well.
The expressed mission of the SCBB is to provide placental cord blood units of high safety and quality, through the practice of internationally accredited techniques of collection, processing, banking and disposition, in order to support cord blood transplantations and related research in Singapore and around the world.
SCBB is registered in Singapore as a company limited by guarantee. It has a not-for-profit charter and is governed by a non-executive board of directors. Chaired by Prof Tan Ser Kiat the board's members include Mr Gregory Vijayendran, Mr Markham Shaw, Dr Chong Tsung Wen, Dr Mary Rauff and A/Prof Allen Yeoh.
Chief Executive Officer, Mrs Tan-Huang Shuo Mei, leads the management team of SCBB, having taken over the reins from Mr Steven J Sobak in July 2015. Mr Sobak helmed as SCBB's CEO from 2007 to 2015, and Dr Fidah Alsagoff was SCBB's founding Executive Director from inception to early 2007. The Medical Director is Dr William Hwang and the Senior Manager-Operations who takes care of the daily operations is Mr Arun Prasath.
The laboratory and cryo-storage area of SCBB is located at Basement 1 of the KK Women's and Children's Hospital. SCBB has an administrative office at Novena Specialist Centre.
SCBB currently collects cord blood from three public hospitals, namely KK Women's and Children's Hospital, National University Hospital and Singapore General Hospital, as well as all 7 of the private obstetric hospitals in Singapore, Gleneagles Hospital, Mount Alvernia Hospital, Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital, Parkway East Hospital, Raffles Hospital and Thomson Medical Centre.
Bone marrow is a semi-solid tissue found within the spongy portions of bones. In birds and mammals, bone marrow is the primary site of new blood cell production. It is composed of hematopoietic cells, marrow adipose tissue, and supportive stromal cells. In adult humans, bone marrow is primarily located in the ribs, vertebrae, sternum, and bones of the pelvis. Bone marrow comprises approximately 5% of total body mass in healthy adult humans, such that a man weighing 73 kg (161 lbs) will have around 3.7 kg (8 lbs) of bone marrow.
In placental mammals, the umbilical cord is a conduit between the developing embryo or fetus and the placenta. During prenatal development, the umbilical cord is physiologically and genetically part of the fetus and normally contains two arteries and one vein, buried within Wharton's jelly. The umbilical vein supplies the fetus with oxygenated, nutrient-rich blood from the placenta. Conversely, the fetal heart pumps low-oxygen, nutrient-depleted blood through the umbilical arteries back to the placenta.
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous, allogeneic or syngeneic.
Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. GvHD is commonly associated with bone marrow transplants and stem cell transplants.
A cord blood bank is a facility which stores umbilical cord blood for future use. Both private and public cord blood banks have developed in response to the potential for cord blood in treating diseases of the blood and immune systems. Public cord blood banks accept donations to be used for anyone in need, and as such function like public blood banks. Traditionally, public cord blood banking has been more widely accepted by the medical community. Private cord blood banks store cord blood solely for potential use by the donor or donor's family. Private banks typically charge around $2,000 for the collection and around $200 a year for storage.
Anthony Nolan is a UK charity that works in the areas of leukaemia and hematopoietic stem cell transplantation. It manages and recruits donors to the Anthony Nolan Register, which is part of an aligned registry that also includes the Welsh Bone Marrow Donor Registry, NHS Blood and Transplant's British Bone Marrow Registry and Deutsche KnochenMarkSpenderdatei (DKMS) UK. This aligned register is known as the Anthony Nolan & NHS Stem Cell Registry. It also carries out research to help make bone marrow transplants more effective.
Canadian Blood Services is a non-profit charitable organization that is independent from the Canadian government. The Canadian Blood Services was established as Canada's blood authority in all provinces and territories except for Quebec in 1998. The federal, provincial and territorial governments created the Canadian Blood Services through a memorandum of understanding. Canadian Blood Services is funded mainly through the provincial and territorial governments.
Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders such as cancer. There is growing interest from cell therapeutics companies in developing genetically modified allogenic natural killer cells from umbilical cord blood as an alternative to CAR T cell therapies for rare diseases.
T-cell lymphoma is a rare form of cancerous lymphoma affecting T-cells. Lymphoma arises mainly from the uncontrolled proliferation of T-cells and can become cancerous.
The National Marrow Donor Program (NMDP) is a nonprofit organization founded in 1986 and based in Minneapolis, Minnesota, that operates the Be The Match Registry of volunteer hematopoietic cell donors and umbilical cord blood units in the United States.
World Marrow Donor Association (WMDA) is an organization based in Leiden, Netherlands, that coordinates the collection of the HLA phenotypes and other relevant data of volunteer hematopoietic cell donors and cord blood units across the globe.
Pablo Rubinstein is a pioneer in freezing of umbilical cord blood or placental blood cells for the use for unrelated donors to treat diseases like leukemia and genetic diseases such as Tay–Sachs disease and sickle cell anemia. He pioneered and established an international cord blood banking system and has played a leading role in international cord blood transplantation.
Juvenile myelomonocytic leukemia (JMML) is a serious chronic leukemia that affects children mostly aged 4 and younger. The name JMML now encompasses all diagnoses formerly referred to as juvenile chronic myeloid leukemia (JCML), chronic myelomonocytic leukemia of infancy, and infantile monosomy 7 syndrome. The average age of patients at diagnosis is 2 years old. The World Health Organization has included JMML in the category of myelodysplastic and myeloproliferative disorders.
The Gift of Life Marrow Registry is a public bone marrow and blood stem cell registry headquartered in Boca Raton, Florida. Gift of Life facilitates transplants for children and adults suffering from life-threatening illnesses, including leukemia, lymphoma, other cancers and genetic diseases.
Relicord is an initiative by the Reliance Industries in the field of biotechnological advancement. It is established as a part of the subsidiary of Reliance Industries, Reliance Life Sciences. ReliCord is the first to have a registered cord blood bank and repository in India as well as the entire region of South East Asia. In terms of Biotechnology India is currently amongst the top five countries in the Asia Pacific region. Reliance Life Sciences and ReliCord are an endeavour by the Reliance Group to tap into this emerging market that has great potential.
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Microtransplantation (MST) is an advanced technology to treat malignant hematological diseases and tumors by infusing patients with granulocyte colony-stimulating factor (G-CSF) mobilized human leukocyte antigen (HLA)-mismatched allogeneic peripheral blood stem cells following a reduced-intensity chemotherapy or targeted therapy. The term "microtransplantation" comes from its mechanism of reaching donor cell microchimerism.
Guo Mei is a hematologist and associate director of 307th Hospital of Chinese People’s Liberation Army and deputy director of Radiation Research Institute.
Cells4Life is a private stem cell bank based in the United Kingdom. It procures, processes and stores human umbilical cord blood and tissue samples that may be used for stem cell treatments. Cells4Life is the largest provider of umbilical cord blood banking services in the UK, with over 50% of the UK market. Based in Burgess Hill, the company also provides umbilical stem cell storage and collection services in Spain, Italy, United Arab Emirates, Bulgaria, Pakistan and Kenya.
Shimon Slavin, M.D., is an Israeli professor of medicine. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for induction of transplantation tolerance to bone marrow and donor allografts.
